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To evaluate the efficacy of cisplatin, gemcitabine, and treosulfan (CGT) in 91 patients with pretreated relapsed AJCC stage IV
cutaneous malignant melanoma. Patients in relapse after first-, second-, or third-line therapy received 40mgm
 2 intravenous (i.v.)
cisplatin, 1000mgm
 2 i.v. gemcitabine, and 2500mgm
 2 i.v. treosulfan on days 1 and 8. Cisplatin, gemcitabine, and treosulfan
therapy was repeated every 5 weeks until progression of disease occurred. A maximum of 11 CGT cycles (mean, two cycles) was
administered per patient. Four patients (4%) showed a partial response; 15 (17%) patients had stable disease; and 72 (79%) patients
progressed upon first re-evaluation. Overall survival of all 91 patients was 6 months (2-year survival rate, 7%). Patients with partial
remission or stable disease exhibited a median overall survival of 11 months (2-year survival rate, 36%), while patients with disease
progression upon first re-evaluation had a median overall survival of 5 months (2-year survival rate, 0%). Treatment with CGT was
efficient in one-fifth of the pretreated relapsed stage IV melanoma patients achieving disease stabilisation or partial remission with
prolonged but limited survival.
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The prognosis for malignant melanoma patients with distant
metastases is poor. Even though a small proportion of patients
can attain long-term survival with systemic therapy, the median
survival of advanced melanoma patients is about 6 months. While
interferon-a continues to be standard in the adjuvant therapy of
resected high-risk melanoma (Hillner et al, 1997), dacarbazine
(DTIC) has been the most widely used agent in the first-line
treatment of stage IV metastatic melanoma, yielding a response
rate of up to 20% (Serrone et al, 2000). Although several DTIC-
based chemotherapy and chemoimmunotherapy combinations
have been reported with response rates between 34 and 53%
(Richards et al, 1992; Huncharek et al, 2001; Atzpodien et al, 2002;
Stein et al, 2002), these regimens have not yielded a significant
survival advantage. Once DTIC-based therapy has failed, no
standard systemic treatment has been available for relapsed
IV-stage malignant melanoma patients.
Preclinical studies on the chemosensitivity of metastatic
melanoma cells to cytotoxic agents identified sensitivity while
using combinations of gemcitabine with treosulfan and gemcita-
bine with cisplatin (Cree et al, 1999; Ugurel et al, 2003). First
results of a phase II trial of 24 metastatic uveal melanoma patients
treated with gemcitabine and treosulfan showed a prolonged
progression-free survival and a slight increase in tumour
responses, when compared to 24 patients treated with treosulfan
alone (Schmittel et al, 2006).
The goal of our present analyses was to evaluate the efficacy of
combined cisplatin, gemcitabine, and treosulfan in pretreated
relapsed stage IV malignant melanoma patients.
PATIENTS AND METHODS
Patients
Between February 2001 and August 2006, 91 relapsed stage IV
cutaneous melanoma patients received a combination treatment
with cisplatin, gemcitabine, and treosulfan (CGT). At start of CGT
therapy, patients showed one metastatic site (n¼46), two
metastatic sites (n¼29), three metastatic sites (n¼13), and four
metastatic sites (n¼2), respectively. Pretreatment serum lactate
dehydrogenase level was elevated in 51% of the patients.
Criteria for entry into the study were: systemically pretreated
relapsed AJCC stage IV cutaneous malignant melanoma; white
blood cell count 43500ml
 1; platelet count 4100000ml
 1;
haematocrit 430%; serum creatinin and bilirubin o1.5 of the
upper normal limit; age between 18 and 80 years, and a life
expectancy of 43 months. Progressive CNS metastases were no
exclusion criteria. Previous systemic cisplatin failures were not
excluded, since cisplatin was used in combination only.
All patients had a Karnofsky performance status 480%.
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sWritten informed consent was obtained from all patients prior
to therapy.
Treatment design
Patients in relapse after first-, second-, or third-line therapy
received 40mgm
 2 intravenous (i.v.) cisplatin, 1000mgm
 2 i.v.
gemcitabine, and 2500mgm
 2 i.v. treosulfan on days 1 and 8.
Therapy was repeated every 5 weeks until progression of disease
occurred.
Dose and schedule was employed according to Pfohler et al
(2003) and Schmittel et al (2005). Cisplatin was added at a
moderate standard dose. Fifty-nine (65%) patients required a dose
reduction due to toxicity.
Response, survival, and toxicity
Response to therapy was evaluated according to World Health
Organization (WHO) criteria with regular re-evaluation intervals
every 2 months; complete response: disappearance of all signs of
disease for a minimum of 2 months; partial response: 50% or more
reduction in the sum of products of the greatest perpendicular
diameters of measurable lesions, no increase in lesion size, and no
new lesions; stable disease: less than a partial response with no
disease progression for at least 5 weeks; progressive disease: 25%
or more increase in sum of products of the longest perpendicular
diameters of measurable lesions or the development of new
lesions.
Survival was measured from start of therapy to date of death or
to the last known date to be alive.
Maximum toxicity was evaluated according to WHO criteria.
Statistical analysis
The statistical end points in our analysis were: (1) rate of response
or disease stabilisation (primary end point) and (2) overall survival
of patients.
The response rate (SD, PR) for patients in relapse after previous
systemic chemotherapy was hypothesised to be at least 5%. Using
an a of 0.05 (two-sided), a sample size of 73 patients was needed to
have 80% power to statistically establish the assumed response
rate. Given the tumour-related patient morbidity, up to 25% drop-
out rate was estimated.
The probability of overall survival and progression-free survival
was plotted over time according to the method of Kaplan and
Meier; SPSS software (SPSS Inc., Chicago, IL, USA) was employed.
RESULTS
Median follow-up of all patients was 6 months (range: 0–29
months). Patient characteristics are listed in Table 1. The patient
group consisted of 59 men and 32 women, at a median age of 58
years. Seventy-two patients had a cutaneous primary, while in
19 patients, the primary was unknown. All patients had failed
previous therapy. Stage IV pretreatment consisted of chemother-
apy, notably, DTIC, Cisplatin, BCNU/Fotemustine (n¼68); DTIC,
BCNU, Hydroxyurea (n¼23); DTIC, CisplatinþVinblastine
(n¼4); DTICþRoferon (n¼4); BCNU/FotemustineþBleomycin,
Vindesine (n¼3); TrofosfamideþTreosulfan, Gemcitabine
(n¼3); and Temozolamide (n¼2). Patients received a mean of
two CGT cycles (range: 1–11) until progression of disease
occurred or until last known date to be alive.
Outcome
Four patients (4%) reached a partial remission, 15 (17%) patients
had stable disease, and 72 (79%) patients exhibited progressive
disease upon first re-evaluation (Table 1).
There was no significant difference in treatment response
between cisplatin-pretreated patients (6% PR; 17% SD; 77% PD)
and noncisplatin-pretreated patients (13% SD; 87% PD).
At the last follow-up, 3 (3%) of the 91 patients are progression-
free (range: 5–26 months). Six-month and 12-month progression-
free survival was calculated at 8.7 and 5.8%, respectively.
Survival
Overall media survival of all 91 patients was 6 months (range: 0–29
months; 1-year survival rate, 17%, 2-year survival rate, 7%)
(Figure 1A). Patients achieving a partial remission or stable disease
(n¼19) exhibited a median overall survival of 11 months (1 and
2-year survival rate, 36%) (Figure 1), while patients with disease
progression (n¼72) upon first evaluation showed a median
overall survival of 5 months (1-year survival rate, 11%; 2-year
survival rate, 0%) (Figure 1). At the last follow-up, 7 (8%) patients
(range: 5–26 months) are alive.
Treatment toxicity
Cisplatin, gemcitabine, and treosulfan therapy was moderate-
to-well tolerated. No toxic deaths occurred. Most haematologic
Table 1 Patient characteristics
CGT
Entered 91
Age (years)
Median 58
Range 18–80
Sex
Male 59
Female 32
Primary
Cutaneous 72
Unknown 19
CGT
Second line 77
Third line 12
Fourth line 2
Stage IV pretreatment
a
DTIC, Cisplatin, BCNU/Fotemustine 68
DTIC, BCNU, Hydroxyurea 23
DTIC,Cisplatin±Vinblastine 4
DTIC±Roferon 4
BCNU/Fotemustine±Bleomycin, Vindesine 3
Trofosfamide±Treosulfan, Gemcitabine 3
Temozolamide 2
Sites of progressive metastatic disease
Skin/soft tissue 38
Lung 33
Visceral 33
Lymph nodes 20
Bone 11
CNS 4
Others 2
Maximum response
Complete remission 0
Partial remission 4
Stable disease 15
Progressive disease 72
Abbreviations: BCNU¼carmustine; CGT¼cisplatin, gemcitabine, and treosulfan;
DTIC¼dacarbazine
aPatients may have had more than one pre-treatment.
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sside effects were limited to WHO grades I and II and were
experienced in 52% (leukopenia), 50% (anaemia), and 29%
(thrombocytopenia) of CGT-treated patients; grade III- or IV-
related haematologic side effects were experienced in 26%
(leukopenia), 20% (thrombocytopenia), and 3% (anaemia) of
patients (Table 2). Eighty-seven per cent of patients showed no
major (WHO grade III/IV) nausea/vomiting, 98% of patients
experienced no major (WHO grade III/IV) polyneuropathy, and
78% of patients showed no other significant toxicities according to
WHO (grade III/IV).
DISCUSSION
The prognosis of patients with relapsed high-risk melanoma failing
standard DTIC-based chemotherapy remains disappointing. How-
ever, recent preclinical studies on the chemosensitivity of metastatic
melanoma cells to cytotoxic agents identified high sensitivity to
cytotoxic single agents including cisplatin, treosulfan, gemcitabine,
as well as to combinations of gemcitabine plus treosulfan and
gemcitabine plus cisplatin (Cree et al, 1999; Ugurel et al, 2003, 2006).
Our present analysis of 91 high-risk AJCC stage IV melanoma
patients failing previous first-, second-, or third-line therapy,
showed a median overall survival of 6 months upon subsequent
treatment with the combination of CGT.
While this is the first report on the effect of CGT on metastatic
cutaneous melanoma, recent results on CGT-treated metastatic
uveal melanoma patients showed a similar median overall survival
of 7.7 months (Schmittel et al, 2005). Other authors reported that
14 metastatic uveal melanoma patients treated with gemcitabine
and treosulfan as first-line therapy (except one) yielded an
objective reponse of 28% and a median overall survival of 61
weeks (Pfohler et al, 2003).
This present multi-agent chemotherapy regimen led to 21% of
patients with stable disease or partial remission, with a prolonged
median overall survival of 11 months. This was even more striking
given the number of prior therapies and the high percentage of
cisplatin-pretreated patients.
However, there was no difference in response between cisplatin-
pretreated and noncisplatin-pretreated patients suggesting that
relapse after previous systemic therapy, that is, prior to the current
regimen, may have been cisplatin unrelated.
In the present group of pretreated metastatic cutaneous
melanoma patients, median overall survival upon CGT treatment
was similar to that reported upon standard DTIC-based therapy,
which yielded a median overall survival of 7 months (Chapman et al,
1999). Similar historical outcome upon current CGT second-/third-/
fourth-line therapy compared with DTIC-based first-line treatment
might be explained by treatment eligibility-related patient selection;
thus, only patients with Karnofsky performance status 480%
despite relapse of disease received subsequent CGT therapy, here.
In summary, treatment with CGT was efficient in one-fifth of
pretreated relapsed stage IV melanoma patients achieving disease
stabilisation or partial remission. In future, it could be beneficial to
prospectively identify melanoma patients, who could benefit from
selected chemotherapeutic agents after failing first- or second-line
standard chemotherapy.
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Figure 1 Overall survival (Kaplan–Meier estimates) of (A) all 91
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gemcitabine, and treosulfan. Survival was measured from start of therapy.
Table 2 Haematologic toxicity
Haematologic toxicity
a
% Patients
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